Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DHIVY vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
DHIVY is not a recognized drug. No dosing information available.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
Not applicable.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
Not applicable.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not applicable.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not applicable.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
No FDA black box warnings.
None.
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No data available for DHIVY.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
Do not use in pregnancy. No dose recommendations available; contraindicated.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Do not use this drug without correct identification.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DHIVY vs ANDEMBRY, answered by our medical review team.
DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DHIVY and ANDEMBRY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DHIVY and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.